Industry analysts now estimate the global oncology drug market could surpass US$900 billion by 2034, fueled by rising demand ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

Bristol Myers Squibb Co. has identified new GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term ...

The firm will evaluate VS-7375 as both monotherapy and in combination with Eli Lilly's EGFR inhibitor Erbitux in the study.

We systematically interrogate KRAS alterations in the TCGA pan‐cancer dataset of human MPM and in MPM patients from our centers employing sensitive techniques. 20% of TCGA and 50% of our patients show ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene - a gene that can cause cancer - that ...

Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene—a gene that can cause cancer—that may ...

The Food and Drug Administration (FDA) has granted accelerated approval to Avmapki ™ (avutometinib) plus Fakzynja ™ (defactinib) for the treatment of adult patients with KRAS- ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene — a gene that can cause cancer — that may play an important role ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with ...